NCT05709067

Brief Summary

The goal of this clinical trial is to compare the effect of a probiotic strain on mental wellbeing in moderately stressed, healthy, adults in the general population. The main question it aims to answer is • what is the impact of probiotic consumption on overall mental wellbeing? Participants will consume one probiotic or placebo capsule per day, answer a set of questionnaire (at 3 time points) and wear a wearable device for the total duration of the study.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Mar 2023

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 19, 2022

Completed
1 month until next milestone

First Posted

Study publicly available on registry

February 1, 2023

Completed
2 months until next milestone

Study Start

First participant enrolled

March 20, 2023

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 16, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 16, 2023

Completed
Last Updated

February 23, 2024

Status Verified

February 1, 2024

Enrollment Period

6 months

First QC Date

December 19, 2022

Last Update Submit

February 22, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in Mental wellbeing

    Improvement in mental wellbeing will be measured using the Oxford Happiness Questionnaire (OHQ). The Oxford Happiness Inventory was devised as a broad measure of personal happiness. The OHQ has a total of 29 items. Each item is scored on a Likert scale from 1 to 6 (1=strongly disagree; 2=moderately disagree; 3=slightly disagree; 4=slightly agree; 5=moderately agree; 6=strongly agree). Some items are phrased positively and others negatively. Such that negative items (1, 3, 12, 13, 16, 18, 21 and 29) should be scored in reverse (Hills \& Argyle, 2002). The total score is then divided by 29. Interpretation of the final score is as follows: A final score between 1 to 2 is considered "not happy"; between 2 and 3 is "somewhat unhappy"; between 3 and 4 is considered "Neutral"; 4 is "somewhat or moderately happy"; between 4 and 5 is "rather happy"; between 5 and 6 is "very happy"; 6 is "too happy".

    4 weeks

Secondary Outcomes (4)

  • Change in Stress scores

    4 weeks

  • Change in anxiety scores

    4 weeks

  • Change in Depression scores

    4 weeks

  • Change in Salivary cortisol

    4 weeks

Study Arms (2)

Probiotic Arm

EXPERIMENTAL
Dietary Supplement: Probiotic

Control

PLACEBO COMPARATOR
Dietary Supplement: Placebo

Interventions

ProbioticDIETARY_SUPPLEMENT

6 Billion CFU per day

Probiotic Arm
PlaceboDIETARY_SUPPLEMENT

0 CFU per day

Control

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adults aged between 18-60 years old
  • Currently living in the US.
  • Have access to a smart phone, internet and computer.
  • Report moderate levels of perceived stress.

You may not qualify if:

  • Are currently taking medication for depression or anxiety
  • Have had antibiotics within the previous month
  • Have an allergy to coconut

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sun Genomics, Inc.

San Diego, California, 92122, United States

Location

MeSH Terms

Interventions

Probiotics

Intervention Hierarchy (Ancestors)

Dietary SupplementsFoodDiet, Food, and NutritionPhysiological PhenomenaFood and Beverages

Study Officials

  • Divya Nair

    SunGenomics

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 19, 2022

First Posted

February 1, 2023

Study Start

March 20, 2023

Primary Completion

September 16, 2023

Study Completion

September 16, 2023

Last Updated

February 23, 2024

Record last verified: 2024-02

Data Sharing

IPD Sharing
Will not share

Locations